300+ Genes
1 Blood Draw
Now FDA-Approved

FoundationOne® Liquid CDx helps guide treatment strategies for advanced cancer patients by analyzing 300+ genes from just two tubes of blood — making it the most comprehensive FDA-approved liquid biopsy on the market.

**Demonstrated Clinical Outcomes Data**
Companion diagnostic claims across multiple targeted therapies and cancer indications

**Comprehensive Panel**
Analyzes 324 genes* from two tubes of blood, providing comprehensive results typically within 10 days† to help inform treatment strategies.

Includes results from genomic signatures:
- Blood Tumor Mutational Burden (bTMB)**
- Microsatellite Instability High (MSI-H)**
- Tumor Fraction™

**Improved Outcomes**
In the TRITON2 Clinical Trial

46% Objective Response Rate

for advanced prostate cancer patients who tested positive for BRCA1/2 alterations and treated with RUBRACA® (rucaparib).†

**Proven Quality**
To receive our FDA approval and demonstrate evidence of our high-quality testing, we ran over 7,500 validation samples covering over 30,000 unique genomic variants across more than 30 cancer indications.

**Proven Portfolio**
Only Foundation Medicine offers an FDA-approved portfolio of tissue- and blood-based comprehensive genomic profiling tests for all solid tumors — with Medicare coverage for qualifying patients.‡

* FoundationOne® Liquid CDx is FDA-approved to report substitutions and indels in 311 genes, including rearrangements in ALK and BRCA1/2 and copy number alterations in BRCA1/2 and ERBB2 (HER2). Comprehensive results across all 324 genes are reported as a laboratory professional service which is not reviewed or approved by the FDA.
† From receipt of specimen.
** bTMB, MSI-H status, and tumor fraction are reported as a laboratory professional service which is not reviewed or approved by the FDA.
‡ For more detailed information visit foundationmedicine.com/F1LCDx
Companion Diagnostic Indications

<table>
<thead>
<tr>
<th>TUMOR TYPES</th>
<th>BIOMARKER(S) DETECTED</th>
<th>THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Small Cell Lung Cancer (NSCLC)</td>
<td>EGFR exon 19 deletions and EGFR exon 21 L858R substitution</td>
<td>Iressa® (gefitinib), Tagrisso® (osimertinib) or Tarceva® (erlotinib)</td>
</tr>
<tr>
<td></td>
<td>ALK rearrangements</td>
<td>Alecensa® (alectinib)</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>PIK3CA mutations C420R, E542K, E545A, E545D [1635G&gt;T only], E545G, E545K, Q546E, Q546R; and H1047L, H1047R, and H1047Y</td>
<td>Piqray® (alpelisib)</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>BRCA1/2 alterations</td>
<td>Rubraca® (rucaparib)</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>BRCA1, BRCA2, ATM alterations</td>
<td>Lynparza® (olaparib)</td>
</tr>
<tr>
<td></td>
<td>BRCA1, BRCA2 alterations</td>
<td>Rubraca® (rucaparib)</td>
</tr>
</tbody>
</table>

FoundationOne® Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

Rubraca® is a registered trademark of Clovis Oncology.

References
2. Medicare and Medicare Advantage members have coverage in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage.